Scientists discover 'genetic goldmine' while studying rice that could change the way we grow our food: 'Valuable resources'
Scientists in China have uncovered a possibly revolutionary development that can help shape the future of a universally utilized grain.
A research team from the Center for Excellence in Molecular Plant Sciences of the Chinese Academy of Sciences published a study in Nature revealing the immense genetic diversity of wild and cultivated rice. The hope is that these findings "provide valuable resources for improving rice varieties in terms of yield, quality, environmental adaptability and resistance to disease and stress."
Asian cultivated rice is a common source of food for billions of people across the world, and boosting the yield is a necessity amid rapid global population growth. Other challenges, like a changing climate and risks of disease and pest exposure, make it a priority to build resistance in these crops.
As part of the study, researchers sequenced 145 rice genomes and created a "pangenome" that reveals the full genetic landscape of wild rice, which is a key step toward understanding the variations needed for crop improvement.
The end result produced a whopping "3.87 billion base pairs of novel genetic sequences," and "nearly 20% of these genes exist only in wild rice, with many linked to traits such as disease resistance and environmental adaptation."
The Chinese Academy of Sciences described the genes as "a 'genetic goldmine' for developing modern rice varieties capable of withstanding pests, disease, and climate challenges."
Breeding resilient and nutritious crops helps ensure food security and provides optimism for the future. Similarly to this study, a research team at UC Davis created a detailed genome sequence for pistachios after studying the nut's DNA, which could bolster crop production and enhance their ability to thrive in extreme weather conditions.
Studies such as these can serve as the foundation for agricultural innovation and plant breeding. Every positive development, no matter how small, could play a crucial role in sustaining our food supply in the face of environmental challenges.
What's the biggest obstacle stopping your organization from using solar panels?
They're too expensive
Don't know where to start
They're an eyesore
We already use solar panels
Click your choice to see results and speak your mind.
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Digital Trends
4 hours ago
- Digital Trends
NASA astronaut's first ISS time-lapse is a real stunner
NASA astronaut Jonny Kim has shared his first-ever time-lapse from aboard the International Space Station (ISS) — and it's a real stunner. The dramatic 68-second clip shows a changing view of Earth as the space-based facility orbits our planet at an altitude of about 250 miles. Recommended Videos 'My first time-lapse,' Kim wrote in a social media post that included the video (below). Kim said he managed to nail it thanks to some time-lapse tips shared by fellow astronaut Nichole Ayers. 'After seeing the result, I told her this felt like fishing,' Kim wrote. 'Prepping the camera, the angle, the settings, the mount, then setting your timer and coming back to hope you got a catch. And after catching my first fish, I think I'm hooked.' My first time-lapse. Thanks to some instruction and tips from @Astro_Ayers, I caught my first aurora. After seeing the result, I told her this felt like fishing. Prepping the camera, the angle, the settings, the mount, then setting your timer and coming back to hope you got a… — Jonny Kim (@JonnyKimUSA) June 6, 2025 The video shows the space station flying into the night, with city lights in Asia and Australia visible far below, and bright stars shining in the far distance. A short while later, a gorgeous aurora appears over the horizon before filling much of the frame. Toward the end of the clip, one of the station's solar arrays also come into view. Auroras are natural light displays in Earth's sky, caused by charged particles from the sun colliding with the Earth's magnetic field and atmosphere. While also viewable from parts of Earth, astronauts on the ISS can also enjoy a unique view of this natural wonder. Indeed, for most astronauts, witnessing auroras is one of the highlights of their time in orbit. Earlier this year, another NASA astronaut, Don Pettit, shared a dramatic view of an aurora, captured as the ISS flew directly over it. Kim arrived at the space station with two Russian cosmonauts after launching aboard a Soyuz spacecraft in April this year. With another four months of his mission left to run, hopefully the American will have time to create more clips similar to his first outstanding effort.
CNN
11 hours ago
- CNN
US reports another arrest of Chinese scientist with no permit to send biological material
Detroit (AP) — A Chinese scientist was arrested while arriving in the U.S. at the Detroit airport, the second case in days involving the alleged smuggling of biological material, authorities said Monday. The scientist is accused of shipping biological material months ago to staff at a laboratory at the University of Michigan. The FBI, in a court filing, described it as material related to certain worms and requires a government permit. 'The guidelines for importing biological materials into the U.S. for research purposes are stringent, but clear, and actions like this undermine the legitimate work of other visiting scholars,' said John Nowak, who leads field operations at U.S. Customs and Border Protection. The scientist was interviewed and arrested Sunday after arriving on a flight from China, where she is pursuing an advanced degree at Huazhong University of Science and Technology in Wuhan. She planned to spend a year completing a project at the University of Michigan. Her shipments, including an envelope stuffed inside a book, were intercepted last year and earlier this year and opened by authorities, the FBI said. The court filing doesn't indicate whether the FBI believes the biological material was dangerous, though U.S. Attorney Jerome Gorgon Jr. said smuggling 'threatens our security.' The government last week charged two Chinese scientists who are accused of conspiring to smuggle a toxic fungus into the U.S. One was turned around at the Detroit airport and sent back to China last year, while the other, a researcher at the University of Michigan, was arrested. She remains in custody.
